FDA: Sun Ten Laboratories sold herbal products as unapproved drugs and broke supplement manufacturing rules at its Irvine, California plant.
What happened
FDA inspected the Irvine, California facility on September 19-21 and 29 and October 5, 2022, and in February 2023 reviewed the company website. Inspectors found manufacturing rule violations, including a zinc lot released before lab results arrived and a zinc level above the company's own limit that was never reviewed. The website review found disease treatment claims, such as "reduce urinary tract infections symptoms," that make the products unapproved new drugs.
What FDA found
The website claims these products treat or prevent diseases, so they are drugs sold without FDA approval.
Section 201(p) and 505(a) of the Act [21 U.S.C. 321(p), 355(a)]Three products treat conditions a person cannot safely diagnose or treat alone, so they cannot carry directions a layperson can follow and are misbranded.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5The company had no real identity, purity, strength or composition limits for its ingredients or finished batches, using vague words like "Positive" and "Confirm" instead of measurable values.
21 CFR 111.70(a), (b)(1), (b)(2), (e); 21 CFR 111.75Quality control released a zinc lot that was over its own zinc limit without a review or disposition decision, and released it before lab results were in.
21 CFR 111.113(a)(1), (b)(2)Master manufacturing records were missing required items such as the full component list, weights, expected yield, label copy and written process instructions.
21 CFR 111.210(b)-(h)Labels were missing the plant part used, the common or Latin name of each ingredient, and required Supplement Facts formatting, and one label was partly in a second language without repeating all required information.
Section 403(f), (i)(2), (q)(5)(F), (s)(2)(C) of the Act [21 U.S.C. 343]; 21 CFR 101.4(h), 101.15(c), 101.36
What FDA wants
FDA asks the company to write to its compliance branch within 15 working days describing each corrective step taken, with supporting documents, and to explain any delay if fixes are not yet complete.
Who should pay attention
- brands that buy herbal or botanical supplements from contract manufacturers
- supplement companies that rely on supplier certificates of analysis instead of their own testing
- retailers and online marketplaces listing herbal products with disease claims
This is a summary. Read the original letter on fda.gov.